1. Scrip
  2. >>Business
  3. >>Earnings

Amgen Optimistic About Growth, Despite Denosumab Biosimilars, Potential Tariffs

MariTide Phase II Obesity Details Planned For ADA

 
• By Mandy Jackson

Amgen saw revenue rise 19% to $33.4bn in 2024 and said revenue should grow to $34.3bn-$35.7bn in 2025 despite losing exclusivity for its biggest franchise – Prolia and Xgeva (denosumab) – this year.

Repatha, Evenity and eight other Amgen products had double- or triple-digit growth in 2024 (Shutterstock)

While regulatory uncertainty in the US is mounting, Amgen does not expect significant revenue impact from new tariffs implemented under US President Donald Trump, chief financial officer Peter Griffith told Scrip. The newly implemented tariffs have prompted questions for big pharmas already coping with the changing US regulatory regime, but Amgen has limited exposure. The company reported strong performance in 2024 on 4 February, with fourth-quarter and full-year 2024 revenues that exceeded analyst consensus and guidance for 2025 that anticipates revenue growth, despite loss of exclusivity for the company’s largest franchise, denosumab.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Merck Forecast Incorporates $200m Tariff Hit

 
• By Joseph Haas

On a quarterly earnings call that touched on Trump administration policy impacts, Merck said it is well positioned for changes coming from the new administration.

BMS Keeping A Watchful Eye On Tariffs, Pricing And Other Policy Changes

 
• By Mandy Jackson

Bristol Myers Squibb’s first quarter revenue beat consensus and the company raised its 2025 guidance, even when including the impact of Chinese tariffs on US products.

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

 
• By Kevin Grogan

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

Roche Moves To Soften Tariff Blow But Admits M&A Dealmaking Could Be Hit

 
• By Andrew McConaghie

Roche believes it can ride out any short-term effects of US tariffs if they are imposed but wants to see reform of US and European pricing to help support the sector.

More from Scrip

Roche Moves To Soften Tariff Blow But Admits M&A Dealmaking Could Be Hit

 
• By Andrew McConaghie

Roche believes it can ride out any short-term effects of US tariffs if they are imposed but wants to see reform of US and European pricing to help support the sector.

In Brief: Boehringer Ingelheim, Tessellate Bio Link For Precision Therapies For ALT Tumors

 
• By Sushmita Panda

In its first pharma collaboration, Tessellate Bio has inked a deal potentially worth more than €500m with Boehringer Ingelheim for therapies for ALT tumors.

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

 
• By Lisa Takagi

Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.